Donidalorsen
BLOOD AND BLOOD FORMING ORGANS
Also known as: dawnzera, donidalorsen sodium, IONIS-PKK-LRx, ISIS 721744
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Donidalorsen is a drug catalogued in DrugCentral. It was first approved by the FDA in 2025. Recorded indications include Hereditary angioneurotic edema.
- Indications: Hereditary angioneurotic edema.
- ATC code: B06AC09 (Drugs used in hereditary angioedema).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hereditary angioneurotic edema
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2026-01-19 | EMA | — | Otsuka Pharmaceutical Netherlands B.V. | Yes |
| 2025-08-21 | FDA | — | Ionis Pharmaceuticals, Inc. | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
B06AC09 | BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Donidalorsen used for?
DrugCentral lists the following indications for Donidalorsen: Hereditary angioneurotic edema.
When was Donidalorsen first approved?
Donidalorsen was first approved by the FDA in 2025.
Browse: all drugs starting with D · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5796 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4650235 — compound record and bioactivity
- FDA UNII ZD4D8M32TL — substance identity
- DailyMed: FDA labels for Donidalorsen — current prescribing information (label search)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.